Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739719 | 0.94 | DPP8 (0.40) | EPHX2NPSR1MEN1ALDH1A1HTT | |
| SCHEMBL482480 | 0.87 | ALDH1A1 (0.41) | EPHX2NPSR1MEN1ALDH1A1HTT | |
| Ammonia Solution, Strong SCHEMBL11635039 | 0.85 | ALDH1A1 (0.41) | EPHX2NPSR1MEN1ALDH1A1HTT | |
| SCHEMBL5614350 | 0.81 | DPP8 (0.41) | EPHX2FAAHCNR1CNR2DPP8 | |
| SCHEMBL5164654 | 0.80 | ALDH1A1 (0.35) | EPHX2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL31732782 | 0.79 | GRIN2D (0.45) | EPHX2DPP8DPP9 | |
| Bromide SCHEMBL11515811 | 0.78 | DNM1 (0.47) | MEN1ALDH1A1HTTKMT2ACNR1 | |
| SCHEMBL16682526 | 0.78 | EPHX2 (0.44) | EPHX2NPSR1MEN1ALDH1A1HTT | |
| SCHEMBL6739715 | 0.77 | ALDH1A1 (0.39) | NPSR1MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL270387 | 0.75 | NPSR1 (0.43) | EPHX2NPSR1MEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0358574-B1 | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-02-17 | — | — | EP | claimed |
| EP-0358574-A1 | Process for the preparation of adamantane-1 derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-03-14 | — | — | EP | claimed |
| EP-2318355-B1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-8309597-B2 | 1,1′-diadamantyl carboxylic acids, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20110269736-A1 | 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-11-03 | — | — | US | disclosed |
| EP-2318355-A1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010010174-A1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| EP-0358574-B1 | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-02-17 | — | — | EP | disclosed |
| US-5015758-A | Process for the preparation of 1-adamantane derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-05-14 | — | — | US | disclosed |
| EP-0358574-A1 | Process for the preparation of adamantane-1 derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-03-14 | — | — | EP | disclosed |
| EP-0358574-A1 | Process for the preparation of adamantane-1 derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269736-A1 | 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use | HSD11B1, HSD17B1, HSD3B1 | EPHX2 1205/4885NPSR1 3019/4885MEN1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.